Skip to content

Restricted Cash at other companies

Baxter International logo
Baxter InternationalBAX
Boston Scientific logo
Boston ScientificBSX
Edwards Lifesciences logo
Edwards LifesciencesEW

Other financials

Income statement

See full
Revenue$199.4M+25.7%
Gross profit$141.4M+29.4%
Operating income-$16.2M+50.3%
Net income-$13.9M+54.6%
EPS (diluted)-$0.43+55.7%

Balance sheet

See full
Cash & equivalents$248.5M-35.2%
Total debt$79.0M-10.5%
Total equity$161.2M+86.0%
Total assets$1.0B+8.7%

Cash flow

See full
Operating cash flow-$26.2M-232%
CapEx$6.9M-26.7%
Free cash flow-$33.1M-91.1%

Valuation

See full
Market cap$3.62B+16.0%

Profitability

See full
Gross margin71%+1.6pp
Operating margin-5.5%-2.2pp
Net margin-7.3%-3.1pp
FCF margin2.4%

Returns & leverage

See full
Return on equity-53.1%-17.4pp
Debt / equity0.5×-0.5×
Current ratio5.2×-0.5×

Where this comes from

Reported directly by iRhythm Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: iRhythm Holdings, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about iRhythm Holdings, Inc. 's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is iRhythm Holdings, Inc. 's restricted cash?
iRhythm Holdings, Inc. (IRTC) reported restricted cash of $8.36M in Q1 2026.
How has iRhythm Holdings, Inc. 's restricted cash changed year-over-year?
iRhythm Holdings, Inc. 's restricted cash decreased by 0.0% year-over-year, from $8.36M to $8.36M.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.